2nd Quarter - Report

OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)

Firm
OGR
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General prescription drug affordability and access. Intellectual Property issues. Advise client on nature and status of various COVID-19 legislative proposals. Provisions related to the pharmaceutical industry; FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act.

LobbyistCovered position, as disclosed
DEAN AGUILLEN —
JEROME MURRAY —
KARISSA WILLHITE —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Medicare/Medicaid MMM

Medicare Part D access and drug pricing negotiation; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act. Compulsory licensing policy issues.

LobbyistCovered position, as disclosed
DEAN AGUILLEN —
JEROME MURRAY —
KARISSA WILLHITE —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 3 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.